Palbociclib patent?

What is the patent status of Palbociclib?

Palbociclib, marketed as Ibrance, is a targeted therapy used to treat certain types of breast cancer. The medication's patent status has been a subject of interest, with various extensions and challenges. [1]

When does the Palbociclib patent expire?

According to a report from DrugPatentWatch.com, the original patent for Palbociclib was filed by Pfizer, the drug's manufacturer, in 2009. The patent granted in 2013 is set to expire in 2029, with additional extensions possible. [1]

Have there been any challenges to the Palbociclib patent?

Yes, Pfizer has faced challenges to the Palbociclib patent from other pharmaceutical companies, seeking to develop and market generic versions of the medication. However, the company has successfully secured additional patent extensions, protecting its market exclusivity. [2]

Comparison to other treatments: How does Palbociclib compare with other cancer therapies?

Palbociclib is often compared with other targeted therapies for breast cancer, such as CDK4/6 inhibitors like Keytruda. Studies have shown that Palbociclib has demonstrated efficacy in slowing disease progression, but its comparison with other treatments has led to discussions about their relative benefits and drawbacks. [3]

Regulatory and market exclusivity implications: What does the Palbociclib patent status mean for patients and the market?

The ongoing patent extensions and potential challenges to Palbociclib's market exclusivity have significant implications for patients, with potential implications for pricing and access to the medication. The regulatory landscape surrounding cancer medications and patents continues to evolve. [4]

References:
[1] DrugPatentWatch.com [https://www.drugpatentwatch.com/patent/US-20130310411]
[2] Pfizer [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-first-quarter-2019-results]
[3] Journal of Clinical Oncology [https://ascopubs.org/doi/full/10.1200/JCO.2017.73.7741]
[4] Nature Reviews Drug Discovery [https://www.nature.com/articles/nrd.2018.26]